The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2026 | Treatment approaches for patients with IDH1-mutated AML & practical considerations
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses current treatment approaches for IDH1-mutated acute myeloid leukemia (AML), highlighting the use of IDH1 inhibitors in combination with either intensive chemotherapy or azacitidine. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So for the IDH1-mutated patient, we would like to give IDH1 inhibitor for all the patients in combination with intensive chemo or in combination with azacitidine. Today, IDH1 inhibitor is only available for patients not eligible for intensive chemo in combination with azacitidine. So azacitidine plus ivosidenib is a standard care for IDH1-mutated AML in first line. For patients eligible to intensive chemo, we continue to give intensive chemo without IDH1 inhibitor for the moment because we are waiting the result of the ongoing clinical trial or randomized intensive chemo plus or minus ivosidenib...
So for the IDH1-mutated patient, we would like to give IDH1 inhibitor for all the patients in combination with intensive chemo or in combination with azacitidine. Today, IDH1 inhibitor is only available for patients not eligible for intensive chemo in combination with azacitidine. So azacitidine plus ivosidenib is a standard care for IDH1-mutated AML in first line. For patients eligible to intensive chemo, we continue to give intensive chemo without IDH1 inhibitor for the moment because we are waiting the result of the ongoing clinical trial or randomized intensive chemo plus or minus ivosidenib. And we hope if this clinical trial is positive, we could give intensive chemo plus ivosidenib for this patient. So today, what we do for the patient with a high IDH1 mutated AML, we try to know if the patient is eligible to intensive chemo. So the patient receives intensive chemo alone without inhibitor. And if the patient is not eligible to intensive chemo, so the patient receives azacitidine plus ivosidenib.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie, BMS, Novartis, Servier, Gilead, Jazz Pharma
